Clinical Trial

Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to find a safe and tolerable dose of navlimetostat in combination with pumitamig that can be given to patients with MTAP-deficient advanced non-small cell lung cancer (NSCLC). The effectiveness of the study drugs will also be studied.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-07.
Trial Details
NCT Number NCT07579221
Lead Sponsor M.D. Anderson Cancer Center
Conditions Non-Small Cell Lung Cancer
Enrollment 17 participants
Start Date 2026-11-30
Primary Completion 2029-08-01 (estimated)
Study Completion 2031-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-05